Oxford BioDynamics
Oxford BioDynamics to Raise £12.0M in Stock Placement, Offering
The company said it will use the proceeds of the transactions, which are subject to shareholder approval, to advance its EpiSwitch diagnostics platform.
Oxford BioDynamics Awarded Grant to Apply EpiSwitch to ICI Cancer Therapy Response
The two-year PACT grant will fund the application of the EpiSwitch technology to the analysis of primary and acquired ICI resistance in several clinical trials.
In Brief This Week: Illumina, UnitedHealthcare, Thermo Fisher Scientific, and More
News items for the in vitro diagnostics industry for the week of Nov. 2, 2020.
In Brief This Week: LabCorp, Intermountain Health, Progenity, and More
News items for the in vitro diagnostics industry for the week of Oct. 26, 2020.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.